 Avidity Biosciences stock was up 55 last week after releasing preliminary data from a Phase 1 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The next price-moving catalyst is the updated Phase 12 MARINA trial data in 2023 likely in mid-2023. 